Eligibility criteria for participating in the study includes:

1. A) Adults, ages 18 and older with nephropathic cystinosis with stable kidney function (defined as less than 20% change in creatinine clearance from prior 12 weeks) and one or more of the following: a) muscle weakness; b) swallowing difficulties; c) progressive visual loss; d) intestinal malabsorption.

or

B) Children ages 13-17 years who do not tolerate or do not take cysteamine (defined by leukocyte cystine levels greater than 5 nmol half-cystine/mg protein for 2 consecutive time points at least 3 months apart during the prior 6 months or parental confirmation of patient intolerance) and worsening clinical manifestations as determined by a physician who is not an investigator on this study.

2. Patients must have a related bone marrow donor who is HLA-matched on 10 of 10 alleles.

3. Patients with adequate physical function as measured by:
   Pre-transplant tests of heart, lungs, kidneys, liver, and other organs and must not have a serious infection, be pregnant, or have undergone a prior stem cell transplant.

Interested subjects should ask their physician to contact Zoe Solsby at the Cystinosis Research Foundation for additional information. Telephone: 949.223.7610 or email: zsolsby@cystinosisresearch.org.